期刊
MILITARY MEDICINE
卷 179, 期 7, 页码 799-805出版社
ASSOC MILITARY SURG US
DOI: 10.7205/MILMED-D-13-00336
关键词
-
资金
- Department of Clinical Investigation at Fort Gordon
The use of platelet-rich plasma (PRP) to facilitate healing of orthopedic-related injuries has gained popularity; however, the clinical benefits are not consistent. Differences may result from variations in growth factor (GF) levels in normal populations. The purpose of this study was to determine if GF levels present in activated PRP preparations differed by gender and age (<= 25 versus >25 years) in a healthy population (N = 102). All GFs analyzed (epidermal growth factor [EGF], hepatocyte growth factor [HGF], insulin growth factor-1 [IGF-1], platelet-derived growth factor-AB [PDGF-AB], platelet-derived growth factor-BB [PDGF-BB], transforming growth factor beta-1 [TGF beta-1], and vascular endothelial growth factor) had higher levels for females and for those <= 25 years old. Of the GFs tested, four of seven were significantly higher (p < 0.05) for females (EGF, HGF, IGF-1, PDGF-BB), the most significant being IGF-1 (female, 85.0; male, 69.3 ng/mL; p < 0.01). Five of seven GFs achieved significance (p < 0.05) for people <= 25 years old (EGF, IGF-1, PDGP-AB, PDGF-BB, and TGF beta-1), with IGF and PDGF-AB achieving p < 0.001 (<= 25 years, 85.1; >25 years, 56.8, and <= 25 years, 7.66; >25 years, 5.77 ng/mL, respectively). Finally, for both genders, most of the GFs were positively correlated with all GFs. This study demonstrated that both age and gender account for variations in specific GFs present in PEP, and this may partially explain some of the inconsistent results of PEP clinical trials.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据